Part 3. Topics in Long-Term Opioid Treatment

1.0 AMA PRA Category 1 credit™

1.0 AANP credit

1.0 ACPE credit

1.0 ANCC credit

Live Activity Date: December 8, 2021 @ 5:00 PM/ET - 6:00 PM/ET

Estimated time to complete activity

1 hour

Target Audience

The Managing Opioid Risk in Acute and Chronic Pain initiative is designed to reach health care professionals (HCPs) involved in the management of patients with pain and licensed to practice in the United States and its territories—particularly those professionals with a Drug Enforcement Agency (DEA) registration to prescribe Schedule II and III drugs.

Statement of Need/Program Overview

The opioid crisis in the United States is now in its third decade. Over time, this crisis has been characterized by the overuse of opioid analgesics to control acute and chronic pain, explosive growth in the number of opioid-related overdoses and deaths, and more recently, a contraction in prescribing of opioid medications, as health care providers (HCPs) struggle to balance the benefits and risks of these powerful medications. Subsequently, the FDA issued risk evaluation and mitigation strategies (REMs) for extended-release/long-acting (ER/LA) and immediate-release (IR) opioids, along with a model for developing the HCP education mandated in these REMS: the FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. The purpose of this program is to educate HCPs on the safe prescribing of opioid analgesics as laid out in the FDA Blueprint.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Review how to safely and effectively manage patients on opioid analgesics, including dose titration, opioid rotation, and taper
2. Specify when referral to a pain specialist is appropriate
3. Identify and manage patients with opioid use disorder
4. List the fundamental elements of addition medicine
5. Discuss how to counsel patients and caregivers about the safe use of opioid analgesics, including proper storage and disposal

Faculty

Chair

Charles E. Argoff, MD

Professor of Neurology
Albany Medical College
Vice Chair Department of Neurology
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center
Albany, New York

Faculty

Marc R. Gerber, MD

MRG Rehabilitation & Pain Medicine
Assistant Clinical Professor
University of Central Florida College of Medicine
Orlando, Florida

Program Agenda

Part 3. Topics in Long-Term Opioid Treatment

Launch: Saturday December 8, 2021 (6:00 – 7:00 pm)
Expiration Date (archived version): December 31, 2022

Introduction	5 minutes
Speaker 1	20 minutes
Speaker 2	20 minutes
Conclusion	5 minutes
Q&A	10 minutes

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the preamble; participate in the pre-test, activity, and pass the post-test with a score of at least 70%; and complete the evaluation. CME certificates will be made available immediately upon successful completion. Emails will be sent to each participant within 24-48 hours after the activity concludes.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Applied Clinical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-408-L08-P). This is an enduring material-based activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and (name of other entity). Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies:

• Charles E. Argoff, MD: Consulting fees (eg, advisory boards): Amgen, BDSI, Collegium, Gruenenthal, Lilly, Lundbeck, Neumentum, Redhill Pharma, Teva, Vertex; contracted research (principal investigators must provide information, even if received by the institution): Abbvie, Amgen, Lilly, Teva; speakers’ bureaus: AbbVie, Amgen, Biohaven, Gruenenthal, Lilly, Lundbeck, Red Hill Pharma, Teva
• Marc R. Gerber, MD: Nothing to disclose
• Bill H. McCarberg, MD, FABM: Consulting fees (eg, advisory boards): Averitas, Lilly, Silex; speakers’ bureaus: Adapt, Silex; stock shareholder (individual stocks/stock options, diversified mutual funds do not need to be disclosed): Johnson and Johnson

The planners, managers, and independent reviewers have the following relevant financial relationships with ineligible companies:

• Michael R. Clark, MD, MPH, MBA: Nothing to disclose
• Rhys Williams, MSN, FNP-C, RN: Nothing to disclose
• Kristin Delisi, NP: Nothing to disclose
• Lindsay Borvansky: Nothing to disclose
• Andrea Funk: Nothing to disclose
• Liddy Knight: Nothing to disclose
• Ashley Cann: Nothing to disclose
• Kim Rodriguez: Nothing to disclose
• Jennifer Kulpa: Nothing to disclose
• Ellen Schneidman: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and ACE do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

This activity is jointly provided by Global Education Group and Applied Clinical Education.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FSA).

This activity is distributed by CMEZone.com